Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index; none of the 15 sources its claims cite is checked for support yet.

State policies regulating short-term limited duration insurance plans and cancer stage at diagnosis

Open access

Abstract

Short-term limited duration insurance plans, which proliferated following 2018 federal regulations, may not provide adequate protections for patients with suspected or newly diagnosed cancer and can destabilize insurance markets for comprehensive insurance plan enrollees. Individuals aged 18-64 years with newly diagnosed cancer from 11 states during 2016-2017 and 2019 were identified from the Surveillance, Epidemiology, and End Results program. Difference-in-differences analyses were used to compare changes in early-stage cancer diagnoses from 2016-2017 to 2019 in states that prohibited vs did not regulate short-term limited duration insurance plans. In adjusted difference-in-differences analyses, early-stage diagnoses increased 0.95 percentage points (95% confidence interval = 0.53 to 1.38, P < .001) in states that prohibited short-term limited duration insurance plans vs did not regulate short-term limited duration insurance plans. State policies resulting in unavailability of short-term limited duration insurance plans were associated with an increased percentage of early-stage diagnoses.

Overview

CoChat Summary

TL;DR

In difference-in-differences analyses of SEER data from 11 states, state policies prohibiting short-term limited duration insurance plans were associated with a 0.95 percentage-point increase in early-stage cancer diagnoses from 2016-2017 to 2019 compared with states with no such regulation. This translated to approximately 650 more early-stage diagnoses in 2019 in prohibiting states.

Key findings

  • Adjusted difference-in-differences analyses showed early-stage diagnoses increased 0.95 percentage points (95% CI = 0.53 to 1.38, P < .001) in states that prohibited short-term limited duration insurance plans vs states that did not regulate them, translating to approximately 650 more early-stage diagnoses in 2019.
  • States with other short-term limited duration insurance policies had less change (−0.71 percentage points, 95% CI = −1.92 to 0.50, P = .25).
  • Relative to states where short-term limited duration insurance plans remained available, early-stage diagnoses increased 0.77 percentage points (95% CI = 0.00 to 1.53, P = .05) in states where legislation stopped the sale of such plans; after excluding states with Medicaid eligibility changes, the increase was 1.03 percentage points (95% CI = 0.71 to 1.35, P < .001), translating to more than 800 more early-stage diagnoses.
  • Results were similar for potentially screening-detectable cancers and other cancers, and falsification tests in individuals aged 65 years and older showed no statistically significant changes in cancer stage by state short-term limited duration insurance status.

Methods

  • Difference-in-differences analysis using Surveillance, Epidemiology, and End Results registry data from 11 states covering 26.5% of the US population.
  • Included 398,190 individuals aged 18-64 years with staged first primary malignancies diagnosed 2016-2019; pre-period was 2016-2017, post-period was 2019, and 2018 was excluded as a washout and phase-in period.
  • Linear probability models accounted for state clustering and adjusted for age, race, ethnicity, sex, metropolitan residence status, marital status, county household income, cancer site, and state and year fixed effects; sensitivity analyses excluded states with Medicaid eligibility changes, and subgroup analyses examined screening-detectable and other cancers.

Limitations

  • The paper states the study is retrospective, and many states enacted other policies during the period that could affect the health insurance market and care delivery and confound findings.
  • The paper states the study was limited to 11 SEER states, which may not be representative, and had only 1-year follow-up after short-term limited duration insurance expansion, so long-term impacts are unclear.
  • The paper states individual insurance plan data are lacking, and it is unclear whether individuals who otherwise would be uninsured might benefit from short-term limited duration insurance plans, though the difference-in-differences results suggest a net harm.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/jncics/pkad060

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Changes in percentage early-stage diagnoses from 2016 to 2019 by (A) state policies restricting short-term limited duration insurance (STLD) plans and (B) state STLD plan availability. STLD plan access was expanded nationally by 2018 federal regulation. Although the figure demonstrates estimates for 2018 for visual purposes in portraying trends, 2018 was excluded from the difference-in-difference analyses as a washout and phase-in period. States with no STLD plan regulation included Georgia, Iowa, Kentucky, and Utah; states that introduced legislation regulating STLD plans but still allowed STLD plans included Connecticut, Hawaii, New Mexico, and Washington; states that prohibited STLD plans included California and New Jersey. States with no STLD plan availability in 2019 included California, New Jersey, and Hawaii; states where STLD plans were available included Georgia, Iowa, Kentucky, and Washington; note cases from Connecticut, Louisiana, and Utah were excluded from these comparisons because of Medicaid eligibility changes. Data source: authors’ analysis of Surveillance, Epidemiology, and End Results data.
Figure 1. Changes in percentage early-stage diagnoses from 2016 to 2019 by (A) state policies restricting short-term limited duration insurance (STLD) plans and (B) state STLD plan availability. STLD plan access was expanded nationally by 2018 federal regulation. Although the figure demonstrates estimates for 2018 for visual purposes in portraying trends, 2018 was excluded from the difference-in-difference analyses as a washout and phase-in period. States with no STLD plan regulation included Georgia, Iowa, Kentucky, and Utah; states that introduced legislation regulating STLD plans but still allowed STLD plans included Connecticut, Hawaii, New Mexico, and Washington; states that prohibited STLD plans included California and New Jersey. States with no STLD plan availability in 2019 included California, New Jersey, and Hawaii; states where STLD plans were available included Georgia, Iowa, Kentucky, and Washington; note cases from Connecticut, Louisiana, and Utah were excluded from these comparisons because of Medicaid eligibility changes. Data source: authors’ analysis of Surveillance, Epidemiology, and End Results data.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 9 Not checked · 24 Own results and interpretations

14 more claims

Create a free account to see all 33 claims and to verify the 7 references still open.

See all claims — free account
  • It may state two separate claims as one. 7
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 5

Metadata

Authors
Barnes, J. M., Kirchhoff, A. C., Yabroff, K. R., & Chino, F.
Affiliations
  • Washington University in St. Louis (US)
  • University of Utah (US)
  • American Cancer Society (US)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Barnes, Justin M
Venue
JNCI Cancer Spectrum
Published
2023-08-12
Volume
7
Issue
5
ISSN
2515-5091 (ISSN-L)
OpenAlex
W4385791107
Cited by
5
References
2
Citations by year
2026: 3 · 2025: 1 · 2023: 1
FWCI
0.73
Type
journal article
Language
en
Open access
Locations
  • JNCI Cancer Spectrum (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • American Cancer Society
  • American Society of Clinical Oncology
  • National Cancer Institute (P30CA008748)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
Keywords
state insurance regulation, cancer stage at diagnosis, early-stage cancer, newly diagnosed cancer, cancer screening
MeSH terms
Humans, Insurance, Neoplasm Staging, Neoplasms, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.